Pioneering Cell Therapies for the Central Nervous System
We are a Salt Lake City-based biotechnology company developing novel macrophage cell therapies. By leveraging the unique biology of macrophages, we are engineering solutions specifically designed to infiltrate, remodel, and treat aggressive solid tumors of the brain.
Overcoming the Limits of CNS Drug Delivery
Treating solid tumors in the brain requires overcoming complex physical and physiological boundaries. Traditional systemic cell therapies face significant hurdles crossing the blood-brain barrier and surviving within the immunosuppressive landscape of intracranial tumors.
Our approach uses local administration into the brain, bypassing systemic barriers entirely. By locally delivering engineered macrophages, these cells migrate through dense tissue, seeking out residual cancer cells that remain after tumor removal, changing the landscape of CNS oncology.
Local Delivery
Administered directly into the central nervous system to establish immediate therapeutic presence.
Innate Migration
Leverages natural macrophage motility to track down invasive cells throughout tissue margins.
Phagocytic Clearance
Engineered to actively engulf and destroy solid tumor cells on contact.
Antigen Presentation
Processes and presents tumor antigens locally to alert and recruit downstream adaptive immunity.
Our Platform
A streamlined process designed to eliminate residual cancer cells in the brain.
1. Engineer
Modifying the patient's own macrophages with specific targeting receptors and persistent immune-activating payloads to dictate anti-tumor behavior.
2. Infiltrate
Utilizing localized administration to position cells directly where needed, allowing them to freely migrate through neural tissue surfaces and margins.
3. Remodel
Recruiting and activating T-cells by engaging in direct cancer cell engulfment and antigen presentation, turning the cold microenvironment hot.
4. Scale
Developing short, high-yield ex vivo manufacturing protocols tailored to primary macrophages to secure clinical and economic scalability.
Therapeutic Pipeline
Advancing targeted cell products through rigorous validation milestones.
Glioblastoma (GBM)
Lead Intracranial Program
Melanoma Brain Metastasis
Platform Extension Program
Partnering & Investors
We selectively share our preclinical validation dataset, proprietary platform architecture, and regulatory roadmaps with qualified institutional investors and strategic industry partners.
Request Secure Data Room Access
Connect with our executive management team to discuss our lead CNS programs, platform development milestones, and seed financing collaboration opportunities.
Contact Executive Team